Brandsma, D.

(Dieta Brandsma)

patient glioma study radiotherapy progression radiation treatment brain cancer tumor necrosis tumour oncol temozolomide pseudoprogression glioblastoma month survival trial factor response lesion phase growth radiation necrosis irinotecan imaging pathway chemotherapy glioma patients adjuvant glioblastoma multiforme treatment-related necrosis inhibitor therapy tumour progression kinase incidence temozolomide chemoradiotherapy adjuvant tmz outcome increase enhancement pseudo-early progression disease progression agent phase ii study protein resection chemoradiotherapy receptor anaplastic effect dysarthria rt /tmz treatment-related van den change review disease minute result symptom occurrence radiation-induced brain tumours e ﬀects adjuvant temozolomide oedema injury tumours oligodendroglioma toxicity multiforme chemo-irradiation william infusion growth factor lippincott wilkin

5 Most Recent Publications

Pseudoprogression and pseudoresponse in the treatment of gliomas (Article) Brandsma, D. Bent, M.J. van den	2009-11-01
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide (Article) Taal, W. Brandsma, D. Bruin, H.G. de Bromberg, J.E.C. Swaak-Kragten, A.T. Smitt, P.A. Es, C.A. van Bent, M.J. van den	2008-07-15
Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature (Article) Hamberg, P. Jonge, M.J.A. de Brandsma, D. Verweij, J. Sleijfer, S.	2008-07-01
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas (Article) Brandsma, D. Stalpers, L.J.A. Taal, W. Sminia, P. Bent, M.J. van den	2008-05-01
Molecular targeted therapies and chemotherapy in malignant gliomas (Article) Brandsma, D. Bent, M.J. van den	2007-11-01

Message*:
Your Email Adress*:
	*: Required fields, please provide an email address so that the RePub team can contact you if needed.